Premium
Metabolic syndrome and endocrine dysfunctions after HSCT in children
Author(s) -
Bajwa Rajinder,
Skeens Micah,
Garee Amy,
Miao Yongjie,
Soni Sandeep,
Pietryga Daniel,
Gross Thomas,
Termuhlen Amanda
Publication year - 2012
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.12002
Subject(s) - medicine , endocrine system , dyslipidemia , pediatrics , short stature , quality of life (healthcare) , obesity , hormone , nursing
MS and endocrine dysfunction(s) are common well‐recognized complications after HSCT . We retrospectively analyzed our data on 160 patients with a median age at transplant of five yr (0.3–23), who had been followed for a median of seven yr (range 3–18) at N ationwide C hildren's H ospital after transplant. Dyslipidemia and MS were seen in 13% and 7.5% patients, respectively, and 58% of these patients were <20 yr of age. Twelve patients met the criteria for diagnosis of MS, but four of these did not meet the I nternational D iabetic F ederation or WHO criteria. Variation in the diagnostic criteria for MS leading to underdiagnosis is discussed. Female gonadal failure (27%) and hypothyroidism (21%) were the most common endocrine dysfunctions, followed by short stature and GH deficiency (17%) each. TBI and younger age at HSCT were associated with the highest burden of long‐term effects, and female sex was more significantly associated with MS ‐related dysfunction (p < 0.05). Uniform diagnostic criteria for MS and close follow‐up after transplant are important for the early diagnosis and management of these late effects, thereby improving the overall quality of life of these patients.